Advicenne to Present Eight Posters on the Positive Results of ADV7103 in the Treatment of Rare Nephrological Diseases at Major International Conferences

Regulatory News:

Advicenne (Paris:ADVIC) (BSE:ADVIC) (Euronext: ADVIC - FR0013296746), a specialty pharmaceutical company focused on the development and commercialization of therapeutic products for rare kidney disease, today announced that eight posters relating to its lead drug candidate, ADV7103, will be presented at major international nephrology conferences in the fall of 2019.

“We are pleased that eight posters relating to ADV7103 have been accepted for presentation at key medical conferences in the coming months,” comments Dr. Luc-André Granier, Co-Founder and CEO of Advicenne, “Advicenne’s participation attests to the quality of our clinical teams and, above all, illustrates the international scientific community’s recognition of this approach to treating highly damaging nephrological conditions such as distal renal tubular acidosis (dRTA) and cystinuria, which lack effective alternative treatments.”

Advicenne will present posters at the following conferences:

Spanish Society of Nephrology (SEN) Annual Congress
(October 5-8, 2019 - A Coruña, Spain)
Two posters:

• Efficacy and safety of a new prolonged release new drug after 6 months treatment on dRTA patients
• Acceptability and safety of a new prolonged release new drug in dRTA. Clinical trial phase II/III

Advicenne will also participate, on October 6^th, in a scientific symposium on the long-term consequences of dRTA and treatment management for the disease.

IPNA 2019: 18^th Congress of the International Pediatric Nephrology Association
(October 17-21, 2019 - Venice, Italy)
Two posters:

• Improved management of blood parameters in distal renal tubular acidosis with ADV7103 versus current treatments
• Improved management of urine parameters in distal renal tubular acidosis with ADV7103 versus current treatments

ISPOR Europe 2019: The International Society for Pharmacoeconomics and Outcomes Research
(November 2-6, 2019 - Copenhagen, Denmark)
One poster:

• The economic impact and variability of managing distal renal tubular acidosis in the UK health care setting

ASN 2019: Annual Conference of the American Society of Nephrology
(November 5-10, 2019 - Washington DC, United States)
Three posters:

• Drug therapy choices for acquired distal renal tubular acidosis by US nephrologists and rheumatologists
• Evaluation of ADV7103 Efficacy and Safety in Cystinuria
• ARENA-2: Twice Daily Alkalization for Primary Distal Renal Tubular Acidosis (dRTA)

About Advicenne